InFlectis BioScience
Nantes
About InFlectis BioScience
InFlectis BioScience is leveraging its leading expertise in the cellular defense system against misfolded proteins and drug discovery to identify and develop small molecules which modulate key proteins involved in misfolded protein disorders. Endoplasmic Reticulum (ER) proteostasis is vital for cellular function and cell survival. Many different perturbations can alter the folding capacity of the ER and may cause accumulation of unfolded or misfolded proteins inside the ER, a cellular condition referred to as ER stress. To safeguard proteostasis, the mammalian ER has a complex machinery to maintain the integrity of cells. This adaptive programme is called the unfolded protein response (UPR).
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $10.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Apr 2024)
- Website: inflectis-bioscience.com
- Phone: +330251252000
Industries & Categories
Biopharma, Biotechnology, Health Care, Medical, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/inflectis-bioscience-4414 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.